Altria Group, Inc. (MO) Business Profile

What it does

Altria Group is a tobacco and nicotine company based in Richmond. Founded in 1985, it serves adult tobacco consumers primarily in the United States. Its chief executive is Salvatore Mancuso.

Its largest business makes and sells cigarettes, principally under the Marlboro brand. The company also sells Black & Mild machine-made cigars and moist smokeless tobacco, which consumers place in the mouth rather than smoke. Its smokeless tobacco brands include Copenhagen, Skoal and Red Seal. Altria also sells on! oral nicotine pouches, which are placed in the mouth, and has an e-vapor business under the NJOY name.

Altria operates through subsidiaries. Philip Morris USA makes cigarettes, John Middleton sells cigars, U.S. Smokeless Tobacco Company makes moist smokeless tobacco, and Helix makes oral nicotine pouches. NJOY contracts with outside importers to supply its e-vapor products. An import and sales ban applies to NJOY ACE, its principal e-vapor product; Altria plans to return to the e-vapor market but has not announced when.

The company is also pursuing heated tobacco products through Horizon, a joint venture with a subsidiary of Japan Tobacco. Heated tobacco products use a device to heat a tobacco consumable without burning it. As of February 25, 2026, the venture had no products in the U.S. marketplace. Altria also holds investments in Anheuser-Busch InBev and Cronos Group.

How it makes money

Altria earns revenue mainly by selling tobacco and nicotine products through its operating subsidiaries. Its smokeable products segment includes cigarettes and cigars; its oral tobacco segment includes moist smokeless tobacco and nicotine pouches. It also reports an e-vapor segment, while its other activities include the Horizon venture, international oral nicotine operations and research and development.

Smokeable products generated $20.5 billion in revenue in FY2025, compared with $21.2 billion in FY2024. Oral tobacco products generated $2.8 billion in FY2025. In the third quarter of 2026, the smokeable segment reported $3.1 billion in adjusted operating companies income, while oral tobacco reported $443 million. Those quarterly income figures are adjusted measures rather than revenue totals.

Sales depend on both the number of products shipped and the prices Altria can realize. In the third quarter of 2026, reported domestic cigarette volumes declined by 2.9%, while smokeable price realization was 4.4%. The company seeks to maximize long-term smokeable profitability while funding investment in smoke-free products. It uses Marlboro in the premium cigarette segment and Basic in discount cigarettes.

The products are consumables sold through wholesalers and retailers. Altria’s operating companies also use promotions, discounts and allowances where permitted. In oral tobacco, growth in on! shipments did not fully offset lower moist smokeless tobacco volumes in the third quarter of 2026: total segment shipments declined 4.3%. The parent company receives dividends and distributions from subsidiaries and dividends on its Anheuser-Busch InBev investment.

Customers and how it sells

Altria’s tobacco products are intended for adult consumers, but its direct customers are principally wholesalers, including distributors, and large retail organizations such as chain stores. Those customers distribute or sell the products to consumers. Altria’s distribution subsidiary provides domestic sales and distribution services to its operating companies.

The business operates primarily in the United States and generates substantially all of its revenue from domestic customers. Substantially all of its cigarettes and oral tobacco products are manufactured and sold to customers in the United States. Middleton sells substantially all of its cigars to U.S. customers, while NJOY sells its e-vapor products to U.S. customers.

Two customers each represented a substantial share of consolidated revenue in FY2025: one accounted for 23.0% and another for 19.0%. The available information does not name them. Altria also has international activities through Helix affiliates and intends to compete in international oral tobacco markets.

For its pouch products, Helix uses retail positioning to reach consumers. Its trade program secured premium positioning in stores representing approximately 90% of its volume. Altria believes that positioning supports awareness and consumer trial.

Suppliers and costs

Philip Morris USA purchases most of its burley and flue-cured leaf tobacco directly from domestic growers under contracts and buys some through leaf merchants. U.S. Smokeless Tobacco Company also uses contracts with domestic growers. Middleton buys leaf through merchants and contracts with an outside importer to supply substantially all of its cigars. NJOY contracts with outside importers for all of its products.

Helix and NJOY purchase tobacco-derived nicotine materials from suppliers. The nicotine used in Altria’s innovative smoke-free products is extracted from tobacco produced in one country, exposing the company to supply risk if it cannot find alternatives. Altria also relies on a few significant manufacturing facilities and a small number of key suppliers and distribution service providers.

Costs include raw materials, manufacturing, distribution, marketing and promotions. Philip Morris USA also makes significant inflation-adjusted payments under healthcare litigation settlements. Altria’s modernization initiative includes centralizing work, outsourcing some transactional activities and automating processes. The company expects cumulative savings of at least $600 million by the end of 2029 and plans to reinvest them in its businesses.

Competitive position

Altria competes across cigarettes, cigars, moist smokeless tobacco, nicotine pouches and e-vapor. Tobacco companies compete on price, taste, product quality, innovation, marketing, packaging and distribution. Altria also faces competition across product categories as consumers move between cigarettes, smokeless tobacco and newer nicotine products.

Marlboro is Altria’s principal cigarette brand. In the third quarter of 2026, it held 60% of the premium cigarette segment. Discount cigarettes held 34.1% of the overall category, and Altria uses Basic to compete in discount. Some lower-priced cigarette manufacturers do not make the same healthcare settlement payments as Philip Morris USA.

It was reported on 28 October 2026 that on!’s share of the nicotine-pouch category had slipped to around 14% as Philip Morris International’s ZYN gained a larger share. Altria’s own measure showed on! retail share of 8.3% in the broader oral tobacco category in the third quarter of 2026. The two shares use different categories and periods.

Our reading: Marlboro’s established position and Altria’s distribution relationships give it a substantial brand and retail presence, although discount competition tests that position. Our reading: Helix’s retail positioning supports its pouch business, but competing pouch brands and consumers’ movement away from moist smokeless tobacco limit the protection from Altria’s existing oral portfolio.

Growth opportunities

Altria’s growth plans center on expanding its smoke-free portfolio while continuing to manage the cigarette business for long-term profitability. Its products and projects include on! nicotine pouches, NJOY e-vapor products and heated tobacco through Horizon. Altria also aims to compete internationally in oral tobacco and develop a path into heated tobacco and e-vapor markets outside the United States.

Helix expanded on! PLUS 12-milligram pouches nationally across mint, wintergreen and tobacco in the third quarter of 2026. It subsequently introduced Blueberry Mint and Mango Pineapple and planned to add Watermelon Mint in select locations in November. Altria said nicotine pouches represented more than 60% of the total oral tobacco category in the third quarter. On! reported shipment volume increased 13.3% to 47.8 million cans in that quarter.

Altria plans to return to e-vapor but has not announced a date. For heated tobacco, the Horizon venture’s U.S. commercialization plans depend on FDA authorization. Altria is also targeting entry into non-nicotine categories, with broad commercial distribution of at least five products by 2028.

The company has a 2028 goal for mid-single-digit compounded annual growth in adjusted diluted earnings per share from its stated 2022 base. It is reassessing its smoke-free goals because of disruption from illicit e-vapor products and expects to update them when it has more clarity on the legitimate market.

Structural risks

• Declining cigarette demand and downtrading: Consumers are moving between nicotine categories and, under economic pressure, choosing lower-priced products. Altria may be unable to raise premium prices enough to offset declining volumes.
• Regulation and product authorization: The FDA regulates tobacco product design, marketing and distribution. Lengthy reviews and failure to obtain or retain authorization could delay or prevent sales of new products, including heated tobacco products.
• E-vapor competition and litigation: Illicit flavored disposable products have limited growth of authorized e-vapor products. Importation and sale of NJOY ACE are subject to orders that remain in effect during Altria’s appeal. Altria recorded e-vapor goodwill and intangible asset impairments in 2025.
• Supply and operations: Changes in the price, availability or quality of tobacco, nicotine and components could disrupt production or reduce profitability. Altria relies on a few facilities and a small number of key suppliers and distributors.
• Execution of new-product plans: The company may not succeed in bringing products to market that appeal to adult consumers. Horizon’s results depend on regulatory authorizations, market conditions, product development and meeting commercialization milestones.

Bottom line

Our reading

Altria is primarily a U.S. tobacco business whose revenue remains concentrated in smokeable products, with established brands and distribution supporting its position. [item1] Its effort to expand in pouches and other smoke-free products must contend with declining cigarette and moist smokeless volumes, discount competition and regulatory constraints. [item1a] The on! expansion provides another route to consumers, but it also competes in a growing category as Altria’s existing oral products lose volume. [call_prepared]